Provided by Tiger Trade Technology Pte. Ltd.

Novartis AG

163.92
-1.4600-0.88%
Pre-market: 162.59-1.3300-0.81%08:23 EST
Volume:1.84M
Turnover:299.92M
Market Cap:312.76B
PE:22.93
High:164.02
Open:163.87
Low:162.53
Close:165.38
52wk High:167.86
52wk Low:97.72
Shares:1.91B
Float Shares:1.82B
Volume Ratio:0.78
T/O Rate:0.10%
Dividend:4.00
Dividend Rate:2.44%
EPS(TTM):7.15
EPS(LYR):7.15
ROE:30.81%
ROA:11.14%
PB:6.78
PE(LYR):22.93

Loading ...

Trump Asserts Novartis Establishing Eleven Manufacturing Plants in the United States

Deep News
·
8 hours ago

Unnatural Products in Pact With Novartis to Develop Macrocyclic Peptide Therapeutics

Dow Jones
·
Feb 18

U.S. RESEARCH ROUNDUP-Brixmor Property, Mohawk Industries, UDR

Reuters
·
Feb 17

Novartis on Track for Record High Closing -- Data Talk

Dow Jones
·
Feb 14

Novartis Says Vanrafia Late-Stage Data Support Slowing of Kidney Function Decline in IgA Nephropathy Patients

MT Newswires Live
·
Feb 13

Novartis price target raised to CHF 135 from CHF 125 at JPMorgan

TIPRANKS
·
Feb 13

Novartis’ treatment of progressive supranuclear palsy granted orphan designation

TIPRANKS
·
Feb 11

Correction to Super Bowl Ads Article on Feb. 6 and Feb. 7 -- WSJ

Dow Jones
·
Feb 11

Novartis downgraded to Hold from Buy at DZ Bank

TIPRANKS
·
Feb 10

Novartis breaks ground on biomedical research center in San Diego

TIPRANKS
·
Feb 07

Blood Tests and Better-for-You Soda: Super Bowl Ads May Be Healthiest Yet -- WSJ

Dow Jones
·
Feb 06

Novartis Submits Application in China for Groundbreaking Autoimmune Drug

Stock News
·
Feb 06

Novartis price target lowered to CHF 132 from CHF 133 at Citi

TIPRANKS
·
Feb 06

Novartis Faces Mounting ESG and Sustainability Risks That Could Weigh on Reputation, Financing, and Long-Term Value

TIPRANKS
·
Feb 05

Novartis Faces Biggest Patent Expiry Ever but Sees Growth Ahead

Benzinga
·
Feb 05

Novartis reports Q4 core EPS $2.03 vs. $1.98 last year

TIPRANKS
·
Feb 04

Dow Jones Top Company Headlines at 7 AM ET: Wegovy Maker Novo Nordisk's Shares Slump After Guidance Disappoints | GE ...

Dow Jones
·
Feb 04

Novartis Forecasts Profitability Hit From Generic Drug Competition in U.S. -- Update

Dow Jones
·
Feb 04

Novartis 2026 Guidance a Bit Soft on Earnings -- Market Talk

Dow Jones
·
Feb 04

Generic Drug Competition Intensifies, Novartis Forecasts 2026 Profit Decline

Stock News
·
Feb 04